American Society of Hirudotherapy

Competitive inhibition of heparinase by persulfonated glycosaminoglycans: a tool to detect heparin contamination

Research article published in Analytical chemistry (2011)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportAntimicrobial ResistanceSafety & Infection ControlAich U et al. · Analytical chemistry, 2011

Abstract

Heparin and the low molecular weight heparins are extensively used as medicinal products to prevent and treat the formation of venous and arterial thrombi. In early 2008, administration of some heparin lots was associated with the advent of severe adverse effects, indicative of an anaphylactoid-like response. Application of orthogonal analytical tools enabled detection and identification of the contaminant as oversulfated chondroitin sulfate (OSCS) was reported in our earlier report. Herein, we investigate whether enzymatic depolymerization using the bacterially derived heparinases, given the structural understanding of their substrate specificity, can be used to identify the presence of OSCS in heparin. We also extend this analysis to examine the effect of other persulfonated glycosaminoglycans (GAGs) on the action of the heparinases. We find that all persulfonated GAGs examined were effective inhibitors of heparinase I, with IC(50) values ranging from approximately 0.5-2 μg/mL. Finally, using this biochemical understanding, we develop a rapid, simple assay to assess the purity of heparin using heparinase digestion followed by size-exclusion HPLC analysis to identify and quantify digestion products. In the context of the assay, we demonstrate that less than 0.1% (w/w) of OSCS (and other persulfonated polysaccharides) can routinely be detected in heparin.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsArea Under CurveChondroitin SulfatesChromatography, GelChromatography, High Pressure LiquidDrug ContaminationGlycosaminoglycansHeparinHeparin LyaseKineticsProtein Structure, TertiarySulfonic Acids

Summary

Heparin and the low molecular weight heparins are extensively used as medicinal products to prevent and treat the formation of venous and arterial thrombi.

Why This Matters for Hirudotherapy

This biochemical study found that persulfonated glycosaminoglycans, including the oversulfated chondroitin sulfate (OSCS) implicated in the 2008 contaminated-heparin adverse events, competitively inhibit bacterial heparinase I (IC50 roughly 0.5-2 micrograms/mL), and on that basis the authors developed a heparinase-digestion plus size-exclusion HPLC assay able to detect under 0.1% OSCS contamination in heparin. It is tangential to hirudotherapy itself but relevant to the wider anticoagulant and enzyme-pharmacology context the ASH evidence library tracks, showing how an enzyme's substrate specificity can be turned into a quality-control tool for a widely used blood thinner. As an in-vitro analytical-methods study, it validates a contamination assay and the inhibition behavior of these compounds, and does not address clinical use of heparin, leeches, or any treatment outcome.

Citation

Competitive inhibition of heparinase by persulfonated glycosaminoglycans: a tool to detect heparin contamination

Aich U et al. · Analytical chemistry, 2011

Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.